ASIT biotech - Ahead of schedule on gp-ASIT+
In a transparent announcement, ASIT Biotech’s board has released the conclusions from its recent meeting. Recruitment for the pivotal Phase III study of gpASIT+ for grass pollen allergies is ahead of schedule with the first patient dosed in January and top-line results are expected before the end of 2019. A €9.0m two-tranche convertible debt placing will extend ASIT’s cash runway to Q320, whereas cash at the end of FY18 was €8.5m.Asit Biotech SA. Asit Biotech SA, formerly Biotech Tools SA, is a Belgium- based company that develops products aimed to prevent negative response of the immune system.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.